Background: Corydalis yanhusuo W.T. Wang (YHS) is a well-known Chinese flowering herbal plant commonly used for centuries in functional food and traditional Chinese medicine. In the present study, we have identified and characterized a novel inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) with low toxicity, alkaloid extract of YHS, which suppressed angiogenesis that plays a fundamental role in a wide spectrum of physiological functions and pathological processes. Methods: Proliferative ability of human umbilical vascular endothelial cells (HUVECs) was assessed using MTT assay and Ki67 immunofluorescence staining. Migration ability of HUVECs was evaluated by wound healing and transwell assays. In vitro angiogenesis was tested by spheroid sprouting and tube formation assays. In vivo vascularization was examined using Matrigel plug and chick chorioallantoic membrane (CAM) models. Protein expression and phosphorylation levels of VEGFR2, AKT, ERK and STAT3 were determined by Western blot assay. Results: We demonstrated that alkaloid extract of YHS significantly inhibited a variety of VEGF-induced angiogenesis processes including proliferation, migration, sprouting, and tube formation of HUVECs. Moreover, alkaloid extract of YHS contributed to reduced in vivo neo-vessel formation in Matrigel plugs of mice and CAM models. Further mechanistic studies revealed that alkaloid extract of YHS suppressed VEGF-induced signaling pathway as evaluated by diminished phosphorylation of VEGFR2 and subsequently attenuated its downstream regulators including phospho-ERK1/2, phospho-AKT and phospho-STAT3 levels in HUVECs. Conclusion: Collectively, these preclinical findings indicate that alkaloid extract of YHS remarkably limits angiogenesis and may serve as a promising anti-angiogenic drug candidate.
Metastasis and chemoresistance remain key challenges in colon tumor management. Integrating transcriptomic screening with molecular modeling may reveal actionable therapeutic targets for rational nanocomplex design. Transcriptomic datasets GSE44076 (n = 98) and GSE253699 (n = 6) were analyzed using limma (adjusted p < 0.05, |log₂FC| > 1). Differentially expressed genes were intersected with curated metastasis and chemoresistance panels which resulted in 18 overlapping targets. Hub genes were identified via STRING and Cytoscape-BiNGO, and prognostic analysis using KMplotter highlighted PDCD4 and CCND1 as favorable markers. A PTX-TP@PLGA-iRGD nanocomplex was designed by co-encapsulating paclitaxel and Trametes robiniophila Murr-derived metabolites within a PLGA matrix functionalized with iRGD. Nanocomplexes were characterized by dynamic light scattering, zeta potential, and HPLC for size, stability, and drug encapsulation. Functional validation included docking, 50 ns MD simulations, in vitro cytotoxicity uptake, and target engagement assays. PDCD4 and CCND1 emerged as convergence nodes, with PDCD4 showing stage-wise downregulation (p = 0.014) and positive correlation with immune infiltration. The nanocomplex exhibited a uniform particle size (~ 165 nm, PDI 0.12), and encapsulation efficiency > 75%. In vitro, PTX-TP@PLGA-iRGD demonstrated superior cytotoxicity (IC₅₀ ≈ 4.5 nM in HCT116; 6.5 nM in HT-29) compared to PTX-TP@PLGA and free PTX. Cellular uptake increased ~ 2.8-2.9× with iRGD modification, confirming receptor-mediated endocytosis. Clonogenic assays showed the lowest surviving fraction (~ 22-28%), and PDCD4 expression was upregulated (~ 2.2-fold HCT116; ~1.9-fold HT-29) following treatment. Docking revealed strong PDCD4-ligand affinities (- 6.0 to - 9.6 kcal/mol), and MD trajectories were stable (RMSD 4-6.5 Å; Rg 25-26.5 Å). The study identifies PDCD4 as a key therapeutic target and demonstrates that the PTX-TP@PLGA-iRGD nanocomplex enhances drug potency, selectivity and molecular engagement. This study offers a promising strategy to overcome metastasis and chemoresistance in colon cancer. Not applicable.